Current Edition

hemochromatosis

LaJolla Pharma launches mid-stage study of LJPC-401 in iron overload disorder

LaJolla Pharmaceuticals initiates a Phase 2 clinical trial assessing LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis, a deficiency of the hormone hepcidin which leads …

Continue Reading →